Computational modeling of tumor response to vascular-targeting therapies--part I: validation (Q34725648)

4 August 2017

Computational modeling of tumor response to vascular-targeting therapies--part I: validation (English)

1 reference

4 August 2017

Jana L Gevertz

1

1 reference

4 August 2017

23 March 2011

1 reference

Computational and Mathematical Methods in Medicine

4 August 2017

1 reference

4 August 2017

2011

1 reference

4 August 2017

830515

1 reference

Creative Commons Attribution 3.0 Unported

4 August 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

maintained by WikiProject

WikiProject Mathematics

0 references

cites work

A spatial model of tumor-host interaction: application of chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Prediction of drug response in breast cancer using integrative experimental/computational modeling

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

A novel three-phase model of brain tissue microstructure

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Modes of resistance to anti-angiogenic therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Estimating the cost of new drug development: is it really 802 million dollars?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Key factors in the rising cost of new drug discovery and development

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Vascular targeting agents as cancer therapeutics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Fundamental Concepts of the Angiogenic Process

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

VEGF-VEGF receptor complexes as markers of tumor vascular endothelium

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Malignant glioma: genetics and biology of a grave matter.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Angiogenesis in cancer and other diseases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Glioblastoma multiforme: the terminator

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Simulated brain tumor growth dynamics using a three-dimensional cellular automaton.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Numerical simulation of a stochastic model for cancerous cells submitted to chemotherapy.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.

7 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Regression and regrowth of tumour cords following single-dose anticancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Modeling the effects of vasculature evolution on early brain tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Simulating tumor growth in confined heterogeneous environments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Growing heterogeneous tumors in silico.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

A change of strategy in the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F830515

Chemotherapeutic drug transport to brain tumor

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065055

In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21461361

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21461361

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21461361

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2011/830515

1 reference

4 August 2017

journals/cmmm/Gevertz11

1 reference

DBLP Dataset 2021-01-02

28 January 2021

1 reference

4 August 2017

1 reference

PubMed ID

21461361